Medication overuse headache …

Chia-Chun Chiang MD

Headache & Pain

Updated 09.15.2024
Released 02.14.1994
Expires For CME 09.15.2027

Medication overuse headache

Author: Chia-Chun Chiang MD

See Contributor Disclosures

Editor: Shuu-Jiun Wang MD

Medication overuse headache

In This Article

Quick Link

Introduction

Overview

Medication overuse headache is a chronic headache that occurs in people with a preexisting primary headache, such as migraine or tension-type headache, following overuse of any kind of acute headache medication. In this update, the author provides an update on the definition, pathophysiology, clinical aspects, and treatment strategies of this headache type.

Key points

	• Medication overuse headache is a common and disabling disorder that affects 1% to 2% of the general population. It is extremely important to recognize and treat this condition.
	• Overuse of acute headache medications can lead to the development of medication overuse headache.
	• In general, treatment of medication overuse headache requires a multidisciplinary setting and includes education of patients, discontinuation of the overused medication, and initiation of preventive treatment. The results of the Medication Overuse Treatment Strategy (MOTS) patient-centered randomized trial were published in April 2022 and demonstrated that, for patients with chronic migraine with medication overuse, migraine preventive medication without switching or limiting the acute medication is not inferior to migraine preventive medication with switching to a different acute medication, suggesting optimizing preventive medication is crucial for the treatment of medication overuse headache (106).

Historical note and terminology

Chronic headache following overuse of acute migraine drugs was described first by Horton and Peters (55). They reported 52 patients with migraine who took ergotamine daily and developed daily headache, and the authors noted improvement after the ergotamine was withdrawn.

The International Headache Society originally defined drug-induced headache as chronic headache occurring on 15 or more days a month following overuse of any kind of acute headache drugs (52). This, however, was based on experience with overuse of analgesics and ergots only and did not cover the triptan-induced medication overuse headache. After triptans were introduced, it became clear that they can also lead to medication overuse headache (59; 68; 67). The revised second edition of the classification criteria of the International Headache Society introduced the term “medication overuse headache,” which replaced previous terms such as “drug-induced headache,” “analgesic-induced headache,” and “rebound headache.” It further differentiated between medication overuse headaches induced by analgesics, ergots, triptans, and opioids (78). In 2006, an expert board consensus paper introduced of broader concept of medication overuse headache in which the diagnosis of medication overuse headache is based on the headache frequency (greater than or equal to 15 days a month) and overuse of headache medication but does not require the headache to improve after withdrawal (77). In 2013, the International Headache Society published the third beta version of the classification criteria, and the ICHD-3 diagnostic criteria was published in 2018. In the ICHD-2, medication overuse headache excluded a concomitant diagnosis of chronic migraine. However, according to the ICHD-3 Beta, as well as the ICHD-3 criteria, because it is unknown whether the overuse of medication is the cause or consequence in an individual case, the patient will receive a diagnosis of both chronic migraine and medication overuse headache when both criteria are met (53).

In the ICHD-3, medication overuse headache is defined in chapter 8 under section 8.2. The diagnostic criteria are as follows:

(A) Headache occurring on 15 or more days per month in a patient with a preexisting headache disorder

(B) Regular overuse for greater than 3 months of one or more drugs that can be taken for acute and/or symptomatic treatment of headache.

It usually, but not invariably, resolves after the overuse is stopped.

It has eight subforms: medication overuse headache induced by ergotamine, triptans, non-opioid analgesics (including paracetamol, NSAID, and acetylsalicylic acid), opioids, combination analgesic, undefined multiple drug classes, and others. Another new section is 8.3, which defines withdrawal headache due to withdrawal from opioids, caffeine, oestrogens, and other substances.

Notably, medication overuse headache refers to when medication overuse is the cause of the headache, whereas the term medication overuse describes the fact that the use of acute medications exceed the specific threshold and does not assume medication overuse to be the cause of the headache.

Table 1. ICHD-3 Section 8.2: Medication Overuse Headache

Diagnostic criteria:
	(A) Headache occurring 15 or more days per month in a patient with a preexisting headache disorder
	(B) Regular overuse for more than 3 months of one or more drugs that can be taken for acute and/or symptomatic treatment of headache
	(C) Not better accounted for by another ICHD-3 diagnosis
Table 2. Sub-Entities of Medication Overuse Headache
	8.2 Medication-overuse headache 8.2.1 Ergotamine-overuse headache 8.2.2 Triptan-overuse headache 8.2.3 Non-opioid analgesic-overuse headache 8.2.3.1 Paracetamol (acetaminophen)-overuse headache 8.2.3.2 Non-steroidal anti-inflammatory drug (NSAID)-overuse headache 8.2.3.2.1 Acetylsalicylic acid overuse headache 8.2.3.3 Other non-opioid analgesic overuse headache 8.2.4 Opioid-overuse headache 8.2.5 Combination analgesic-overuse headache 8.2.6 Medication-overuse headache attributed to multiple drug classes not individually overused 8.2.7 Medication-overuse headache attributed to unspecified or unverified overuse of multiple drug classes 8.2.8 Medication-overuse headache attributed to other medication 8.3 Headache attributed to substance withdrawal 8.3.1 Caffeine-withdrawal headache 8.3.2 Opioid-withdrawal headache 8.3.3 Oestrogen-withdrawal headache 8.3.4 Headache attributed to withdrawal from chronic use of other substance

Clinical manifestations

Presentation and course

The prevalence of medication overuse headache in the general population is 1%, and as high as 11% to 70% in people with chronic daily headache. Some medications carry an increased risk of developing medication overuse headache. Triptans, opioids, and combination analgesics are most commonly associated with medication overuse headache (31). In the recent decade, the use and overuse of ergots decreased significantly worldwide. In Europe, very few patients overuse the combination of analgesics with barbiturates, which is much more frequent in the United States (27; 129; 10). Patients with medication overuse headache are mostly women, on average 40 to 45 years of age. Most of them have migraine, but some of them have tension-type headache or a combination of both. On average, they suffer from primary headache for 20 years and overuse medication for about 5 years (27; 129; 10).

Clinical features of medication overuse headache seem to depend on the pharmacology of the overused substances. For example, unlike patients who suffer from medication overuse headaches following ergot or analgesic overuse, migraine patients (but not patients with tension-type headache) who overused triptans did not describe the typical tension-type daily headache but rather a migraine-like daily headache (a unilateral, pulsating headache with autonomic disturbances) or a significant increase in migraine frequency (see the International Headache Society criteria for triptan-induced medication overuse headache). The delay between the frequent medication intake and the development of daily headache is shortest for triptans (1.7 years), longer for ergots (2.7 years), and longest for analgesics (4.8 years).

A study investigated the frequency of acute medication overuse in the migraine population based on the Chronic Migraine Epidemiology and Outcomes (CaMEO) study (ClinicalTrials.gov, NCT01648530) (105). Among the 16,789 respondents with migraine, 2975 (17.7%) met the criteria for acute medication overuse, and about one third of them reported 15 or more headache days a month, potentially meeting criteria for medication overuse headache. Participants with medication overuse were more likely to have moderate-to-severe depression and anxiety as measured by the PHQ-9 and GAC-7 and higher headache-related disability as measured by the MIDAS score. Of note, the study also reported that overuse of opioids was associated with a lower likelihood of employment [OR (95% CI) = 0.61 (0.47–0.79)].

A multicenter, comprehensive medication overuse headache registry (RELEASE) in Korea started enrolling patients with medication overuse headache in 2020 (82). The data of 229 patients were analyzed and demonstrated that the mean duration of chronic headache and medication overuse was 6.5 and 4.3 years, respectively, and patients had headaches 25 days per month, with 25 days of acute medication use before enrollment. Comorbid moderate/severe depression and anxiety were reported in 56% and 35% of patients, respectively. The proportion of patients on preventive treatments increased from 38% to 93% during the study period. The studies demonstrated a high level of disability in migraine patients with medication overuse.

Clinical vignette

A 38-year-old woman presented to the headache clinic and reported suffering from daily headaches. Her migraine had started at the age of 15 years. She usually had two to three migraine attacks per month. During the past 3 to 4 years, the migraine frequency had increased to five to six attacks per month, each lasting 2 to 3 days. She sometimes treated her migraine attacks with triptans or a combination of aspirin, paracetamol, and caffeine. Her migraines increased in frequency, and she consequently increased her drug intake until she was taking medication 15 to 18 days per month. During the last 2 to 3 years, she experienced dull, bilateral headaches in addition to her typical migraine attacks. During the past year, she had taken more headache drugs because of increasing days with bilateral tightening headache.

She was advised to undergo drug withdrawal. She developed a withdrawal headache, which was treated for 5 days with an oral prednisone taper. A preventive treatment with topiramate was initiated. Two months later, the patient was experiencing three to four migraine attacks per month, each lasting 1 to 2 days. Concomitant, dull daily headache disappeared completely.

Biological basis

Etiology and pathogenesis

The incidence of developing chronic headache for people with episodic headache is about 2% to 3% in one year (99).

According to current knowledge the following risk factors lead to the development of medication overuse headache:

Migraine and tension-type headaches as primary headache. Most headache experts agree that generally patients with migraine and tension-type headaches have a higher risk of developing medication overuse headache than patients with no primary headache using analgesics for other diseases. For example, patients who were consuming fairly large amounts of analgesics regularly for arthritis did not show an increased incidence of headache (65; 06). However, clinical series reported medication overuse headache in patients with cluster headache (80) and shunted hydrocephalus (127; 24), interestingly in those patients with a positive family history of migraine. In both observations, frequency and intensity of headache decreased after reducing analgesic intake.

Overuse of any kind of acute headache medication. A very important question of whether use of specific classes of acute headache drugs bears a higher risk for development of medication overuse headache was addressed in the American Migraine Prevalence and Prevention (AMPP) Study. Of 8219 individuals with episodic migraine, 209 developed chronic headache during the following year. The incidence of de novo chronic headache was 2.5%. People using medication containing barbiturates or opiates had a two-fold higher risk of developing chronic headache than those using single analgesics or triptans (10). A large, population-based, case-control study revealed caffeine consumption to be a modest risk factor for chronic daily headache development (98).

Over the past several years, four newer migraine-specific acute medications became available, namely, ubrogepant, rimegepant, zavegepant, which are CGRP receptor antagonists, and lasmiditan, which is a serotonin 5-HT1F agonist. As gepants and CGRP antagonism are also used as preventive therapy for migraine, it is believed those medications do not cause medication overuse headache. This is supported by a rodent model of medication overuse headache study confirming that ubrogepant does not induce latent sensitization (74), whereas lasmiditan has the capacity to induce medication overuse headache as it provoked cutaneous allodynia in a rat model (91).

Socioeconomic status and obesity. Low socioeconomic status is associated with chronic headache and medication overuse headache in Norway (51; 125) and was even more prominent in countries in transition such as Russia and the Republic of Georgia (57; 04).

Obesity and metabolic syndrome have increasingly been recognized as an important risk factor for medication overuse headache (29). In a longitudinal, 1-year, population-based study, Scher and associates demonstrated that obese individuals were five times more likely to develop chronic headache than people of normal weight (99). Another U.S. study found a significant association between obesity and chronic headache (09). The result analysis from the CaMeo study also suggested that patients with acute medication overuse were more likely to have a BMI of 30 kg/m² or greater, less likely to have a 4-year college degree, and more likely to have headaches more than 15 days per month as compared to participants without medication overuse (105).

Psychiatric and other comorbidities. Several studies looked at family history and comorbidities of patients with medication overuse headache. Depression and anxiety are more frequent in patients with medication overuse headache and seem to increase the risk of developing chronic headache by 50% (02; 97). It seems that patients with medication overuse headache more frequently have a positive family history of chronic headache and substance abuse (16). Insomnia (96), temporomandibular disorders (22), mood disorders, dependency like behavior (45), or use of psychoactive substances are more frequent in patients with medication overuse headache (89), especially in those with preexisting episodic tension-type headache (03). Stress seems to be an important factor in chronicity as well. A Danish study that followed 129,150 people demonstrated a strong association of patients with medication overuse headache with healthy lifestyle behavior and stress (126). Another prospective population-based German study demonstrated that increased stress perception was associated with an increase of headache frequency (102).

Pathophysiology. The pathophysiology of medication overuse headache still remains unclear. The number of animal studies has increased significantly. Reuter and colleagues demonstrated that chronic exposure of triptans causes a down-regulation of receptors in trigeminal ganglion and, subsequently, a reduction of receptor function (92). Chronic administration of sumatriptan and zolmitriptan caused a decrease of the 5-HT synthesis in the dorsal raphe nuclei of the brainstem (121; 34).

Triptan given daily resulted in a sensitization of trigeminal nociception, possibly due to increased expression of neuronal nitric oxide synthase in dural afferents (23). Green and colleagues also investigated the electrical threshold for cortical spreading depression and stress-induced activation of trigeminal afferents in a rat model of medication overuse headache. They reported that a previous period of sumatriptan exposure led to increased susceptibility to evoked cortical spreading depression and stressed-induced activation of the trigeminal nucleus caudalis. The authors concluded that lower cortical spreading depression threshold, and enhanced consequences of cortical spreading depression events may represent an underlying mechanism for medication overuse headache (47). Chronic application of analgesics resulted in up-regulation of pronociceptive 5HT2A receptors of platelets in humans (113), in a significant decrease in the maximum number of 5HT2A binding sites and an increase in the maximum number of 5-HT transporter binding sites in the CNS of rats (114).

Genetic studies on medication overuse headache are ambiguous. Park and colleagues reported an association of a serotonin transporter protein gene polymorphism (short allele) with medication overuse in chronic tension-type headache (83). In contrast, an Italian study did not find significant associations between medication overuse headache risk and 5HT2A gene polymorphisms (119). Another study suggested a possible role of Wolframin His611Arg (WFS1) polymorphism in medication overuse and subsequent medication overuse headache. Homozygous or compound heterozygous mutations in WFS1 (chromosome 4p16.1) determine Wolfram syndrome, a neurodegenerative disorder associated with diabetes mellitus, diabetes insipidus, hearing loss, progressive blindness, and a heterogenous combination of psychiatric disorders. Heterozygous Wolfram syndrome carriers are prone to develop psychiatric illness or behavioral problems, such as impulse control and alcohol or illicit drug abuse (33). A systematic review of gene polymorphism studies in medication overuse headache indicated the potential role of candidate polymorphic variants of the dopaminergic gene system as risk factors for medication overuse headache susceptibility. However, the authors indicated that definite conclusions cannot be drawn due to methodological flaw in some studies (13). A case-controlled study in Taiwan analyzed the whole-genome single nucleotide polymorphism genotyping on 605 migraine patients from the headache clinic in a tertiary center as well as 6055 controls from the Taiwan Biobank (56). It reported that patients with migraine carrying human leukocyte antigen (HLA)-B*58:01 or HLA-C*03:02 had 1.63 (1.11-2.39)-fold likelihood to have chronic migraine with medication-overuse headache compared to episodic migraine and that screening for HLA-B*58:01 has the potential to alleviate the burden of medication overuse headache in migraine. The study provides important insights on the genetic basis and potential clinical implication of medication overuse headache (56). Emphasizing the genetic influence of headache disorder, a published review summarized that changes in genes including COMT, GIT2, ZNF234, and SOCS1 have been associated with migraine progression to medication overuse headache (132).

There is growing evidence that central sensitization may play an important role in the pathophysiology of chronic headache. A series of investigations using psychophysical and electrophysiological techniques clearly demonstrated a facilitation of trigeminal pain processing in patients with chronic headache. Decreased pain thresholds have been found in patients with chronic tension-type headache (08). These findings have been confirmed by demonstrating increased amplitudes of laser-evoked cortical potentials in patients with chronic tension-type headache (25). Ayzenberg and colleagues used a novel technique of simultaneously recording blink reflex and nociceptive cortical potentials following nociceptive trigeminal stimulation. The authors were able to demonstrate a temporary facilitation of the trigeminal nociceptive system at a supraspinal level that normalized again after withdrawal (05). Using transcranial magnetic stimulation, Currà and colleagues demonstrated an increase of cortical inhibitory mechanisms in NSAID-induced headache but not in patients overusing triptans (21).

Imaging studies provide further insights into the pathophysiology of medication overuse headache. Both structural (100; 93) and functional (40; 36) changes in the pain matrix of the brain have been identified. For structural neuroimaging, voxel-based morphometry studies showed decreased gray matter volume in pain-processing areas including orbitofrontal cortex (62). Results from functional MRI studies suggested changes in the mesocorticolimbic dopamine pathway (36) as well as the pain modulatory area, especially frontal regions (63). Changes of the pain processing areas and their connections to the antinociceptive nuclei of the brainstem have also been reported (72).

Psychological factors include the reinforcing properties of pain relief by drug consumption, a powerful component of positive conditioning. Many patients report that they take migraine drugs prophylactically because they are worried about missing work or an important social event or they fear an imminent headache. They are often instructed by physicians or by the instructions supplied with the medication to take the migraine drug as early as possible at the start of either the aura or the headache phase of a migraine attack.

Withdrawal headache is an additional factor. When the patient tries to stop or reduce the medication, the preexisting headache worsens. Barbiturates that are contained in drugs used to treat tension-type headache have a high potency for addiction. The stimulating action of analgesics or migraine drugs and their psychotropic side effects, such as sedation or mild euphoria, may lead to drug dependency. Barbiturates, codeine, other opioids, and caffeine are most likely to have this effect. Caffeine increases vigilance, relieves fatigue, and improves performance and mood (48; 49). The typical symptoms of caffeine withdrawal, such as irritability, nervousness, restlessness, and “caffeine withdrawal headache,'' (123; 112), which may last for several days, encourage patients to continue their abuse. Despite the fact that caffeine may enhance the analgesic action of acetylsalicylic acid and acetaminophen, caffeine-containing combinations should not be used. Similarly, caffeine and meprobamate, the main metabolite of carisoprodol, should be removed from ergotamine-containing formulations.

Headache patients can develop physical dependence on codeine and other opioids (131; 37). Although some headache patients have been on codeine for as long as 10 years, no studies have investigated the effects of codeine intake over this time period. It should be remembered that up to 10% of codeine is metabolized to morphine.

Epidemiology

Epidemiological studies on the consumption of analgesics in the general population clearly indicate that analgesics are widely overused all over the world, in developed as well as developing countries. According to these surveys, between 1% and 3% of the general population take analgesics on a daily basis, and up to 7% take them at least once a week (103; 50).

Population-based prevalence studies demonstrate that about 1% to 2% of the general population suffer from chronic daily headache combined with overuse of headache medication. This is true for the United States and Canada, South America, and Europe (15; 87; 66; 18; 115), and it is also true according to the studies for Korea (84). Studies in post-Soviet countries reported a significantly higher prevalence of chronic headache of 10% and of chronic headache with medication overuse of 6% (04). The only study from Africa in Zambia reported a high prevalence of probable medication overuse headache of 7.1% (70). From an analysis of the MAST study (Migraine in America Symptoms and Treatment), acute medication overuse was present in 15% of respondents with migraine, and was more likely in patients who overused triptan, opioid, and barbiturates but less likely in NSAID users (104).

Meskunas and colleagues performed a retrospective analysis in order to evaluate the overuse of acute headache drugs in a United States center over the past 15 years. The proportion of subjects with a diagnosis of medication overuse headache remained stable over the years, varying from 64% of all cases seen in the center in 1990 to 59.3% in 2005. The authors found a significant decrease in the relative frequency of probable ergotamine overuse headache (from 18.6% to 0%) and in probable combination analgesic overuse headache (from 42.2% to 13.6%). The relative frequency increased significantly for the triptans (from 0% to 21.6%), for simple analgesics (from 8.8% to 31.8%), and for combinations of acute medications (from 9.8% to 22.7%). These data indicated that medication overuse headache remained an important problem in tertiary headache care but that the profile of medication overuse has dramatically changed (71).

Several studies addressed the prevalence of chronic headache in adolescents. One Taiwanese study revealed a prevalence of chronic daily headache in a population of adolescents (12 to 14 years of age) of 1.5%. Only 20% of them overused headache medication, confirming previous findings that medication overuse is less prevalent in children and adolescents (124). A study from Canada reported a clinical analysis of 1669 children with headache seen in a neurology outpatient clinic. The prevalence of chronic headache was 3%. The prevalence of medication overuse, however, was significantly higher, at about 52% (73). In contrast, some studies report a higher prevalence of pediatric medication overuse headache both in general practice clinics and tertiary headache institutions (85). A multi-national study in Europe and Latin America demonstrated that use of electronic medical diaries improved the outcome of patients suffering from medication overuse headache after withdrawal from overused drugs (117).

Differential diagnosis

When evaluating chronic headache patients, it is necessary to take a careful history. These patients frequently take several different substances daily despite the fact that their effect is negligible. Patients should record their present and prior use of prescription drugs, nonprescription compounds, and caffeine intake. Many patients also abuse other substances, such as tranquilizers, opioids, decongestants, and laxatives. It is often helpful for patients to keep a diagnostic headache diary for one month in order to actually record headache patterns and drug use. History and examination should also search for possible complications of regular drug intake, such as recurrent gastric ulcers, anemia, and ergotism. A good indicator is the number of physicians the patient has consulted and the number of previous unsuccessful therapies. One study showed that headache patients had consulted an average of 5.5 physicians who had prescribed 8.6 different therapies (28).

All conditions that lead to more than 10 to 12 headache days per month must be considered in the differential diagnosis of medication overuse headache. Chronic tension-type headache is a diffuse, dull, nonlocalized headache with or without minimal autonomic features. Headache intensity is lower than that of migraine. Patients find it difficult to describe the character of pain. Sometimes it is described as a feeling of a metal band around the head or a feeling of increased pressure. Many patients with chronic tension-type headache complain of mild autonomic disturbances such as nausea, photophobia, or phonophobia.

Patients with chronic migraine have a history of episodic migraine attacks that increase in frequency over time. Chronic migraine is diagnosed if patients have headaches for more than 15 days per month, and at least 8 days with migrainous features (eg, unilateral throbbing pain, moderate to severe in intensity; nausea or vomiting; photo- and phonophobia; and headache intensity that is increased by physical activity). The majority of patients are women, 90% of whom have a history of migraine without aura.

Hemicrania continua patients suffer from daily headache of moderate intensity. Superimposed exacerbation of severe headache with ipsilateral autonomic features, such as ptosis, miosis, tearing, and sweating (75; 76) may occur. Some patients have photo- and phonophobia or nausea. In some cases, the head pain alternates sides. Hemicrania continua is differentiated from cluster headache and chronic paroxysmal hemicrania by its continuous pain character; furthermore, the autonomic symptoms during acute pain exacerbations are less pronounced compared with cluster headache or chronic paroxysmal hemicrania.

Patients with new daily persistent headache abruptly develop chronic headache without remission. Many patients remember the exact day the headache started. These patients did not have a previous history of migraine or episodic tension-type headache. In some patients a viral infection was suspected to cause this form of headache (26). The headache usually does not respond to ergots, triptans, or simple analgesics.

Management

There are three main strategies to treat medication overuse headache: abrupt discontinuation of the overused medication without preventive therapy, adding preventive therapy without abrupt discontinuation of the overused medication, or adding preventive therapy plus abrupt discontinuation of the overused medication. Nonpharmacological behavioral interventions should also be incorporated. A systematic review of the treatment of medication overuse headache was published from the available literature (17). The majority of the medication overuse headache treatment trials were done to evaluate the efficacy of early discontinuation with preventive medication. The studies showed encouraging outcome in reducing headache frequency and medication consumption. However, most trials were done without control groups. Abrupt discontinuation without preventive therapy is often complicated by withdrawal symptoms and high relapse rate. For preventive therapy without early discontinuation of the overused medication, there are large, randomized control trials supporting the use of onabotulinum toxin A and topiramate, however, the trial was done on patients with chronic migraine and medication overuse and data were obtained from post-hoc analysis.

An open-label, randomized clinical trial was conducted at the Danish Headache Center (14). A total of 120 patients were randomly assigned in a 1:1:1 fashion to (1) withdrawal plus preventive treatment, (2) preventive treatment without withdrawal, or (3) withdrawal with optional preventive treatment 2 months after withdrawal. At 6-month follow up, the headache days per months were reduced by 12.3, 9.9, and 9.5 in the three groups, respectively. The percentage of patients reverted to episodic headache were 74.2%, 60.0%, and 41.7%. The authors concluded that all three treatment strategies were effective, but withdrawal therapy combined with preventive therapy from the start of withdrawal is recommended as treatment for medication overuse headache. Another large, randomized trial, the Medication Overuse Treatment Strategy (MOTS) Trial is currently ongoing involving 29 sites in the U.S. to compare the effect of (1) adding migraine preventive therapy with immediate discontinuation of the overused medication and (2) migraine preventive therapy without immediate discontinuation of the overused medication.

For abrupt discontinuation of the overused medications, the typical withdrawal symptoms last for 2 to 10 days (average 3 and a half days) and include withdrawal headache, nausea, vomiting, arterial hypotension, tachycardia, sleep disturbances, restlessness, anxiety, and nervousness. Seizures or hallucinations were only rarely observed, even in patients who were abusing barbiturate-containing migraine drugs.

Drug withdrawal is performed differently. A consensus paper by the German Neurological Society recommends outpatient withdrawal for highly motivated patients who do not take barbiturates or tranquilizers with their analgesics (30). Patients who take tranquilizers, codeine, or barbiturates and who failed to withdraw the drugs as outpatients or who have a high depression score can be offered inpatient treatment. The decision of withdrawal setting, however, differs and depends on the political and economic circumstances in different countries. The medical evidence is scarce.

Brief instruction to patients with medication overuse headache about the importance of restricting use of acute headache medications per postal mail without contact to medical personnel is effective and leads to significant reduction of medication overuse and subsequently to improvement of chronic headache (44). Brief education to patients with medication overuse headache can be done by general practice clinics and is very effective as demonstrated in a BIMOH study in Norway. Here, 50 general practitioners received a 1-day training by headache experts. Thereafter, 25,486 patients allocated to the 50 general practitioners were screened for medication overuse headache. Identified cases were invited by general practitioners to receive a brief education about medication overuse headache. This simple intervention was effective: chronic headache was resolved in 50% of cases, and the headache frequency was reduced by 7.3 days per month (60).

Several studies compared the efficacy of inpatient versus outpatient withdrawal and reported no differences between the two settings (116; 94; 20). Another study demonstrated that psychological education alone is equally effective as a cognitive behavioral contact program (39). Therefore, we suggest an outpatient withdrawal in the first instance in uncomplicated patients with medication overuse headache. Patients with psychiatric or psychological comorbidities should be treated using a multidisciplinary treatment approach (41). An Italian headache group from Pavia established a stratified approach for medication overuse headache patients with and without comorbidities. They were able to show that simple medication overuse headache can be treated equally successfully using in- and outpatient approaches, whereas more complicated patients (eg, psychiatric comorbidities, or overuse of benzodiazepines or barbiturates) could be admitted to the hospital, if necessary (95).

Treatment recommendations for the acute phase of drug withdrawal vary considerably between studies. They include fluid replacement, analgesics, tranquilizers, neuroleptics, amitriptyline, valproate, intravenous dihydroergotamine, oxygen, and electrical stimulation. Studies on cortisone to reduce withdrawal headache are ambiguous. The first open trial showed that cortisone effectively reduced withdrawal symptoms, including rebound headache (61). A small pilot placebo-controlled study in Germany demonstrated the superiority of oral prednisone 100 mg versus placebo (81). Larger studies from Norway and Germany, however, were negative (11; 88).

Management of medication overuse headache should be performed using multimodal approach (eg, involving psychologists and physiotherapists), which results in significant improvement of headache, improvement of well-being, and a reduction of the illness-related costs. On average, about 70% of patients improve significantly. The medication-related costs decrease by 25%, and in patients overusing triptans, it decreases by 43% (107).

Some studies reported protocols for abrupt discontinuation of the overused medication when admission is necessary. In the hospital, all pain or headache medication is stopped abruptly. Fluids should be replaced by infusion if frequent vomiting occurs. Vomiting can be treated with antiemetics (eg, metoclopramide or domperidone). The withdrawal headache can be treated with nonsteroidal anti-inflammatory drugs (eg, naproxen 500 mg twice daily). In some countries, aspirin is available in injectable form and 1000 mg are given every 8 to 12 hours. If the headache has migrainous features and the patient has not abused ergotamine, intravenous dihydroergotamine 1 to 2 mg every 8 hours is given (90; 110; 111). Prednisone 100 mg on the first day, tapering by 20 mg for the next days, is highly effective. Symptoms of opioid withdrawal can be treated with clonidine. The initial dose is 0.1 to 0.2 mg three times daily, and this is titrated up or down based on withdrawal symptoms (tachycardia, tremor, sleeping disturbances). Some patients may require anxiolytic medication; this should be given for no longer than a week. Patients need the support of treating physicians and nurses as well as encouragement from family and friends. Behavioral techniques, such as relaxation therapy and stress management, should be initiated as soon as the withdrawal symptoms fade.

Outpatient treatment is the preferred approach for patients with medication overuse headache. Before more evidence becomes available for the treatment of medication overuse headache, our recommendation is to initiate a preventive medication and to withdraw the overused medications, together with a multidisciplinary approach as outlined above. A short course of oral prednisone or nonsteroidal anti-inflammatory drugs could be considered for withdrawal symptoms. Studies showed that patients respond to prophylactic treatment with beta-blockers, flunarizine, or valproic acid after drug withdrawal despite the fact that these drugs had been unsuccessful before (19).

Calcitonin gene-related peptide (CGRP)-targeted therapy has emerged as an important treatment option for migraine. Although there have not been clinical trials specifically investigating the use of calcitonin gene-related peptide monoclonal antibodies for treating medication overuse headache, several subgroup analyses of phase 3 trials for the treatment of migraine have demonstrated that the calcitonin gene-related peptide monoclonal antibodies are effective in patients who have chronic migraine with medication overuse. For erenumab, post-hoc analysis for patients with medication overuse showed that erenumab, both the 70 or 140 mg groups, had greater reductions than the placebo group at month 3 in monthly migraine days (mean -6.6 and -6.6 vs. -3.5 days, p < 0.001 for both groups vs. placebo), and acute migraine-specific medication treatment days (-5.4 and -4.9 vs. -2.1, p < 0.001 for both groups vs. placebo) (118). For fremanezumab, a post-hoc analysis of the medication overuse subgroup from the fremanezumab phase 3 randomized-controlled trials showed that fremanezumab treatment significantly reduced the days of acute headache medication use over the 12‐week treatment period compared to placebo (−9.0 ± 0.41 vs. −7.1 ± 0.46 days, p=0.0017). Additionally, significantly more fremanezumab‐treated patients reported no medication overuse during the 12‐week treatment period compared to placebo (55% vs. 46% patients, p=0.0389) (109).

Eptinezumab, a CGRP monoclonal antibody designed to be given intravenously every 3 months, was also shown to be effective and tolerable in phase 3 clinical trials (PROMISE-1 and PROMISE-2) and was approved by the U.S. Food and Drug Administration in February 2020 (01; 108). The PROMISE-2 trials were conducted in patients with chronic migraine who had headaches between 15 and 26 days per month, with at least 8 monthly migraine days. Patients with medication overuse were eligible, with the exception of those who overused opioids or barbiturates (5 or more days of use per month were excluded). A total of 40.2% of patients had medication overuse headache at baseline. There was a significant reduction in acute medication use days at week 12 from baseline compared to placebo in both the 100 mg and 300 mg dose groups (69). Specifically, for the 431 patients who received both a diagnosis of chronic migraine and medication overuse headache at baseline, there was a significant reduction in monthly migraine days in both dose groups (100 mg: -8.4 versus -5.4 days in placebo, p < 0.0001; 300 mg: -8.6 versus -5.4 days in placebo, p < 0.0001). The 50% and 75% responder rates were also higher in patients treated with eptinezumab compared to placebo (32). Furthermore, atogepant, a CGRP receptor antagonist, was also found to be effective in reducing medication overuse, in that 41.8%, 44.7% and 24.7% participants in the 60 mg, 30 mg, and placebo group, respectively, eliminated medication overuse in their double-blind, randomized controlled trials (43). The results are encouraging, suggesting the efficacy of CGRP-targeting therapy as effective treatment options for patients with chronic migraine with medication overuse.

Since CGRP monoclonal antibodies became available in 2018, there have been several real-world patient experiences published around the world. Lambru and colleagues reported a prospective analysis of the patient experience of erenumab treatment in a tertiary headache center in the United Kingdom (64). The study included 162 patients with chronic migraine who had failed at least three preventive treatments, including 91% who had tried onabotulinum toxin A injections. The percentage of patients with medication overuse was reduced from 54% at baseline to 20% at month 3 and 25% at month 6. Ornello and colleagues also reported that in an Italian real-world study that included 89 patients, 64 (71.9%) had medication overuse (79). After 3 months of erenumab treatment, 53 (69.7%) had a 50% decrease in monthly migraine days. Furthermore, 46 (71.9%) of 64 patients were no longer overusing acute headache medications. Among the 76 patients who completed 6 months of erenumab treatment, the median monthly migraine days decreased from 19 to 4 (p < 0.001). The mean monthly days of acute medication use decreased from 10 to 2 days per month, and the mean number of days of triptan use decreased from 5 to 1 (p< 0.001). Of note, the significant reductions in medication use were observed after the first dose of the injection. The real-world studies provide encouraging results for the treatment of patients with migraine and medication overuse; a significant reduction in monthly migraine days and medication use days occurred without the need for discontinuation of the overused medication.

A systematic review and metaanalysis of randomized controlled studies evaluated the efficacy of topiramate, onabotulinumtoxinA, and CGRP monoclonal antibodies (42). It carefully examined the results of 10 studies and concluded that onabotulinumtoxinA and CGRP monoclonal antibodies were beneficial in reducing monthly migraine days and greater than or equal to 50% response rate, and there is currently insufficient evidence to determine the efficacy of topiramate in patients with chronic migraine and medication overuse, highlighting the need for further randomized controlled studies.

The results of the Medication Overuse Treatment Strategy (MOTS) patient-centered, open-label, pragmatic randomized clinical trial was published in April 2022 (106). The study aimed to determine the effectiveness of two treatment strategies for patients with chronic migraine and medication overuse: (1) switching from the overused medication to an alternative medication that could be used on a maximum of 2 days per week, and (2) continuing the overused medication without any frequency limit. A total of 720 adult participants were enrolled from various clinics in the United States. The primary outcome measured was the frequency of moderate to severe headache days during weeks 9 to 12, and subsequently during weeks 1 to 2 after randomization. The results demonstrated that migraine preventive medication without switching or limiting the frequency of the overused medication was not inferior to preventive medication with switching for reducing the frequency of moderate to severe headache days. Both treatment strategies demonstrated similar outcomes during the first 2 weeks as well. The study suggests that when managing chronic migraine with medication overuse, optimizing preventive medication is crucial.

Outcomes

Several studies have addressed the long-term outcome of patients with medication overuse headache after successful withdrawal therapy. Success is defined as no headache at all or an improvement of more than 50% in terms of headache days. The success rate of withdrawal therapy within a time window of the first-year months is about 70% (07; 28; 101; 46; 128; 130; 12). Studies with longer observation time of up to 6 years reported relapse rates between 40% and 50% (101; 35; 38; 86; 122). Predictors for relapses after successful withdrawal therapy remain difficult to analyze. Two aspects appear to be important: the type of primary headache (patients with tension-type headache or co-occurrence of migraine and tension-type headache have a higher relapse risk) (28; 101; 35; 58) and a longer duration of regular drug intake (120; 86).

References

01: Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 2020;40(3):241-54. PMID 32075406
02: Ashina S, Serrano D, Lipton RB, et al. Depression and risk of transformation of episodic to chronic migraine. J Headache Pain 2012;13(8):615-24. PMID 23007859
03: Atasoy HT, Atasoy N, Unal AE, Emre U, Sumer M. Psychiatric comorbidity in medication overuse headache patients with pre-existing headache type of episodic tension-type headache. Eur J Pain 2005;9:285-91. PMID 15862478
04: Ayzenberg I, Katsarava Z, Sborowski A, et al. The prevalence of primary headache disorders in Russia: a countrywide survey. Cephalalgia 2012;32:373-81. PMID 22395797
05: Ayzenberg I, Obermann M, Nyhuis P, et al. Central sensitization of the trigeminal and somatic nociceptive systems in medication overuse headache mainly involves cerebral supraspinal structures. Cephalalgia 2006;26:1106-14. PMID 16919061
06: Bahra A, Walsh M, Menon S, Goadsby PJ. Does chronic daily headache arise de novo in association with regular analgesic use. Headache 2003;43:179-90. PMID 12603636
07: Baumgartner C, Wessely P, Bingol C, Maly J, Holzner F. Long-term prognosis of analgesic withdrawal in patients with drug-induced headaches. Headache 1989;29:510-4. PMID 2793455
08: Bendtsen L, Jensen R, Olesen J. Decreased pain detection and tolerance thresholds in chronic tension-type headache. Arch Neurol 1996;53:373-6. PMID 8929161
09: Bigal ME, Liberman JN, Lipton RB. Obesity and migraine. A population study. Neurology 2006;66:545-50. PMID 16354886
10: Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008;48(8):1157-68. PMID 18808500
11: Boe MG, Mygland A, Salvesen R. Prednisolone does not reduce withdrawal headache: a randomized, double-blind study. Neurology 2007;69(1):26-31. PMID 17475943
12: Boe MG, Salvesen R, Mygland A. Chronic daily headache with medication overuse: predictors of outcome 1 year after withdrawal therapy. Eur J Neurol 2009;16(6):705-12. PMID 19236455
13: Cargnin S, Viana M, Sances G, Tassorelli C, Terrazzino S. A systematic review and critical appraisal of gene polymorphism association studies in medication-overuse headache. Cephalalgia 2018;38(7):1361-73. PMID 28870085
14: Carlsen LN, Munksgaard SB, Nielsen M, et al. Comparison of three treatment strategies for medication overuse headache a randomized clinical trial. JAMA Neurol 2020;e201179. PMID 32453406
15: Castillo J, Munoz P, Guitera V, Pascual J. Epidemiology of chronic daily headache in the general population. Headache 1999;39:190-6. PMID 15613213
16: Cevoli S, Sancisi E, Grimaldi D, et al. Family history for chronic headache and drug overuse as a risk factor for headache chronification. Headache 2009;49(3):412-8. PMID 19267785
17: Chiang CC, Schwedt TJ, Wang SJ, Dodick DW. Treatment of medication-overuse headache: a systematic review. Cephalalgia 2016;36(4):371-86. PMID 26122645
18: Colas R, Munoz P, Temprano R, Gomez C, Pascual J. Chronic daily headache with analgesic overuse: epidemiology and impact on quality of life. Neurology 2004;27:1338-42. PMID 15111671
19: Coskun O, Ucler S, Cavdar L, Inan LE. Effect of valproic acid on withdrawal therapy in patients with overuse of chronic daily headache medications. J Clin Neurosci 2007;14(4):334-9. PMID 16647854
20: Creac'h C, Frappe P, Cancade M, et al. In-patient versus out-patient withdrawal programmes for medication overuse headache: a 2-year randomized trial. Cephalalgia 2011;31:1189-98. PMID 21700646
21: Currà A, Coppola G, Gorini M, et al. Drug-induced changes in cortical inhibition in medication overuse headache. Cephalalgia 2011;31(12):1282-90. PMID 21784773
22: da Silva A, Costa EC, Gomes JB, et al. Chronic headache and comorbibities: a two-phase, population-based, cross-sectional study. Headache 2010;50:1306-12. PMID 20163479
23: de Felice M, Ossipov MH, Wang R, et al. Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers. Brain 2010;133:2475-88. PMID 20627971
24: deSouza RM, Toma A, Watkins L. Medication overuse headache - an under-diagnosed problem in shunted idiopathic intracranial hypertension patients. Br J Neurosurg 2014:1-5. PMID 25136917
25: de Tommaso M, Libro G, Guido M, Sciruicchio V, Losito L, Puca F. Heat pain thresholds and cerebral event-related potentials following painful CO2 laser stimulation in chronic tension-type headache. Pain 2003;104:111-9. PMID 12855320
26: Diaz-Mitoma F, Vanast WJ, Tyrrell DL. Increased frequency of Epstein-Barr-virus excretion in patients with new daily persistent headaches. Lancet 1987;1(8530):411-4. PMID 2880216
27: Diener HC, Dahlof CG. Headache associated with chronic use of substances. Olesen J, Tfelt-Hansen P, Welch KM, editors. The headaches. 2nd ed. Philadelphia: Lippincott, Williams & Wilkins, 1999:871-8.
28: Diener HC, Dichgans J, Scholz E, Geiselhart S, Gerber WD, Bille A. Analgesic-induced chronic headache: long-term results of withdrawal therapy. J Neurol 1989;236:9-14. PMID 2915233
29: Diener HC, Dodick D, Evers S, et al. Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurol 2019;18(9):891-902. PMID 31174999
30: Diener HC, Evers S, Fritsche G, et al. Medication overuse headache. In: Diener HC, editor. Guidelines of the German Society of Neurology. Thieme Verlag 2009.
31: Diener HC, Holle D, Solbach K, Gaul C. Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol 2016;12(10):575-83. PMID 27615418
32: Diener HC, Marmura MJ, Tepper SJ, et al. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: subgroup analysis of PROMISE-2. Headache 2021;61(1):125-36. PMID 33314079
33: Di Lorenzo C, Sances G, Di Lorenzo, et al. The wolframin His 611Arg polymorphism influences medication overuse headache. Neurosci Lett 2007;424(3):179-84. PMID 17719176
34: Dobson CF, Tohyama Y, Diksic M, Hamel E. Effects of acute or chronic administration of anti-migraine drugs sumatriptan and zolmitriptan on serotonin synthesis in the rat brain. Cephalalgia 2004;24:2-11. PMID 14687006
35: Evers S, Suhr B, Bauer B, Grotemeyer KH, Husstedt IW. A retrospective long-term analysis of the epidemiology and features of drug-induced headache. J Neurol 1999;246(9):802-9. PMID 10525978
36: Ferraro S, Grazzi L, Mandelli ML, et al. Pain processing in medication overuse headache: a functional magnetic resonance imaging (fMRI) study. Pain Med 2012;13(2):255-62. PMID 21749635
37: Fisher MA, Glass S. Butorphanol (Stadol): a study in problems of current drug information and control. Neurology 1997;48:1156-60. PMID 9153436
38: Fritsche G, Eberl A, Katsarava Z, Limmroth V, Diener HC. Drug-induced headache: long-term follow-up of withdrawal therapy and persistence of drug misuse. Eur Neurol 2001;45(4):229-35. PMID 11385260
39: Fritsche G, Frettloöh J, Hüppe M, et al. Prevention of medication overuse in patients with migraine. Pain 2010;15(2):404-13. PMID 20800968
40: Fumal A, Laureys S, Di Clemente L, et al. Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine. Brain 2006;129:543-50. PMID 16330505
41: Gaul C, van Doorn C, Webering N, et al. Clinical outcome of a headache-specific multidisciplinary treatment program and adherence to treatment recommendations in a tertiary headache center: an observational study. J Headache Pain 2011;12:475-83. PMID 21544647
42: Giri S, Tronvik E, Linde M, Pedersen SA, Hagen K. Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: A systematic review and meta-analysis. Cephalalgia 2023;43(4):3331024231156922. PMID 36856015
43: Goadsby PJ, Friedman DI, Holle-Lee D, et al. Efficacy of atogepant in chronic migraine with and without acute medication overuse in the randomized, double-blind, phase 3 PROGRESS trial. Neurology 2024;103(2):e209584. PMID 38924724
44: Grande RB, Aaseth K, Benth JS, Lundqvist C, Russell MB. Reduction in medication-overuse headache after short information. The Akershus study of chronic headache. Eur J Neurol 2011;18(1):129-37. PMID 20528911
45: Grande RB, Aaseth K, Saltyte-Benth J, Gulbrandsen P, Russell MB, Lundqvist C. The Severity of Dependence Scale detects people with medication overuse: the Akershus study of chronic headache. J Neurol Neursurg Psychiatry 2009;80(7):784-9. PMID 19279030
46: Grazzi L, Andrasik F, D'Amico D, et al. Behavioral and pharmacologic treatment of transformed migraine with analgesic overuse: outcome at 3 years. Headache 2002;42:483-90. PMID 12167136
47: Green AL, Gu P, De Felice M, Dodick D, Ossipov MH, Porreca F. Increased susceptibility to cortical spreading depression in an animal model of medication-overuse headache. Cephalalgia 2013;34(8):594-604. PMID 24335852
48: Griffiths RR, Woodson PP. Caffeine physical dependence: a review of human and laboratory animal studies. Psychopharmacology 1988a;94:437-51. PMID 3131789
49: Griffiths RR, Woodson PP. Reinforcing properties of caffeine: studies in humans and laboratory animals. Pharmacol Biochem Behav 1988b;29:419-27. PMID 3283780
50: Gutzwiller F, Zemp E. Der Analgetikakonsum in der Bevölkerung und socioökonomische Aspekte des Analgetikaabusus. In: Mihatsch MJ, editor. Das Analgetikasyndrom. Stuttgart: Thieme, 1986:197.
51: Hagen K, Vatten L, Stovner LJ, et al. Low socio-economic status is associated with increased risk of frequent headache: a prospective study of 22718 adults in Norway. Cephalalgia 2002;22:672-9. PMID 12383064
52: Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(Suppl 7):1-93. PMID 3048700
53: Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders 3rd edition (beta version). Cephalalgia 2013;33(9):629-808. PMID 23771276
54: Hedenrud T, Babic N, Jonsson P. Medication overuse headache: self-perceived and actual knowledge among pharmacy staff. Headache 2014;54(6):1019-25. PMID 24766349
55: Horton BT, Peters GA. Clinical manifestations of excessive use of ergotamine preparations and management of withdrawal effect: report of 52 cases. Headache 1963;3:214-26. PMID 13964041
56: Huang C, Chen SP, Huang YH, et al. HLA class I alleles are associated with clinic-based migraine and increased risks of chronic migraine and medication overuse. Cephalalgia 2020;40(5):493-502. PMID 31973566
57: Katsarava Z, Dzagnidze A, Kukava M, et al. Primary headache disorders in the Republic of Georgia: prevalence and risk factors. Neurology 2009;73:1796-803. PMID 19933983
58: Katsarava Z, Limmroth V, Finke M, Diener HC, Fritsche G. Rates and predictors for relapse in medication overuse headache: a 1-year prospective study. Neurology 2003a;60(10):1682-3. PMID 12771266
59: Kaube H, May A, Diener HC, Pfaffenrath V. Sumatriptan misuse in daily chronic headache. BMJ 1994;308:1573.
60: Kristoffersen ES, Straand J, Vetvik KG, Benth JŠ, Russell MB, Lundqvist C. Brief intervention for medication-overuse headache in primary care. The BIMOH study: a double-blind pragmatic cluster randomised parallel controlled trial. J Neurol Neurosurg Psychiatry 2015;86(5):505-12. PMID 25112307
61: Krymchantowski AV, Barbosa JS. Prednisone as initial treatment of analgesic-induced daily headache. Cephalalgia 2000;20:107-13. PMID 10961766
62: Lai TH, Chou KH, Fuh JL, et al. Gray matter changes related to medication overuse in patients with chronic migraine. Cephalalgia 2016;36(14):1324–33. PMID 26853805
63: Lai TH, Wang SJ. Neuroimaging findings in patients with medication overuse headache. Curr Pain Headache Rep 2018;22(1):1. PMID 29340793
64: Lambru G, Hill B, Murphy M, Tylova I, Andreou AP. A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 2020;21(1):61. PMID 32487102
65: Lance F, Parkes C, Wilkinson M. Does analgesic abuse cause headache de novo. Headache 1988;38:61-2. PMID 3343127
66: Lanteri-Minet M, Auray JP, El Hasnaoui A, et al. Prevalence and description of chronic daily headache in the general population in France. Pain 2003;102:143-9. PMID 12620605
67: Limmroth V, Katsarava Z, Fritsche G, Przywara S, Diener HC. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 2002;59(7):1011-4. PMID 12370454
68: Limmroth V, Kazarawa S, Fritsche G, Diener HC. Headache after frequent use of new 5-HT agonists zolmitriptan and naratriptan. Lancet 1999;353:378. PMID 9950449
69: Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 2020;94(13):e1365-77. PMID 32209650
70: Mbewe E, Zairemthiama P, Paul R, Birbeck GL, Steiner TJ. The burden of primary headache disorders in Zambia: national estimates from a population-based door-to-door survey. J Headache Pain 2015;16:513. PMID 25924792
71: Meskunas CA, Tepper SJ, Rapoport AM, et al. Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period. Headache 2006;46:766-72. PMID 16643579
72: Michels L, Christidi F, Steiger VR, et al. Pain modulation is affected differently in medication-overuse headache and chronic myofascial pain - a multimodal MRI study. Cephalalgia 2017;37(8):764-79. PMID 27250235
73: Moore AJ, Shevell M. Chronic daily headaches in pediatric neurology practice. J Child Neurol 2004;19:925-9. PMID 15704864
74: Navratilova E, Behravesh S, Oyarzo J, Dodick DW, Banerjee P, Porreca F. Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache. Cephalalgia 2020;40(9):892-902. PMID 32615788
75: Newman LC, Lipton RB, Russell M, Solomon S. Hemicrania continua: attacks may alternate sides. Headache 1992;32:237-8. PMID 1628961
76: Newman LC, Lipton RB, Solomon S. Hemicrania continua: 7 new cases and a literature review. Headache 1993;32:267.
77: Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006;26:742-6. PMID 16686915
78: Olesen J, Lipton RB. Headache classification update 2004. Curr Opin Neurol 2004;17(3):275-82. PMID 15167061
79: Ornello R, Casalena A, Frattale I, et al. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain 2020;21(1):32. PMID 32264820
80: Paemeleire K, Bahra A, Evers S, Matharu MS, Goadsby PJ. Medication-overuse headache in patients with cluster headache. Neurology 2006;67(1):109-13. PMID 16832088
81: Pageler L, Katsarava Z, Diener HC, Limmroth V. Prednisone vs. placebo in withdrawal therapy following medication overuse headache. Cephalalgia 2008;28(2):152-6. PMID 18039339
82: Park HK, Chu MK, Oh SY, et al. Interim analysis of the Registry for Load and Management of Medication Overuse Headache (RELEASE): A multicenter, comprehensive medication overuse headache registry. Cephalalgia 2022;42(6):455-65. PMID 34786971
83: Park JW, Kim JS, Kim YI, Lee KS. Serotonergic activity contributes to analgesic overuse in chronic tension-type headache. Headache 2005;45:1229-35. PMID 16178954
84: Park JW, Moon HS, Kim JM, Lee KS, Chu MK. Chronic daily headache in Korea: prevalence, clinical characteristics, medical consultation and management. J Clin Neurol 2014;10(3):236-43. PMID 25045377
85: Piazza F, Chiappedi M, Maffioletti E, Galli F, Balottin U. Medication overuse headache in school-aged children: more common than expected. Headache 2012;52(10):1506-10. PMID 22822711
86: Pini LA, Cicero AF, Sandrini M. Long-term follow-up of patients treated for chronic headache with analgesic overuse. Cephalalgia 2001;21(9):878-83. PMID 11903281
87: Prencipe M, Casini AR, Ferretti C, et al. Prevalence of headache in an elderly population: attack frequency, disability, and use of medication. J Neurol Neurosurg Psychiatry 2001;70(3):377-81. PMID 11181862
88: Rabe K, Pageler L, Gaul C, et al. Predisone for the treatment of withdrawal headache in patients with medication overuse headache:a randomized, double-blind, placebo-controlled study. Cephalagia 2013;33(3):202-7. PMID 23093541
89: Radat F, Créac’h C, Swendsen JD, et al. Psychiatric comorbidity in the evolution from migraine to medication overuse headache. Cephalalgia 2005;25:519-22. PMID 15955038
90: Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology 1986;36:995-7. PMID 3520384
91: Rau JC, Navratilova E, Oyarzo J, et al. Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache. Cephalalgia 2020;40(9):903-12. PMID 32580575
92: Reuter U, Salomone S, Ickstein GW, Waeber C. Effects of chronic sumatriptan and zolmitriptan treatment on 5-HAT receptor expression and function in rats. Cephalalgia 2004;24:398-407. PMID 15096229
93: Riederer F, Marti M, Luechinger R, et al. Grey matter changes associated with medication-overuse headache: correlations with disease related disability and anxiety. World J Biol Psychiatry 2012;13(7):517-25. PMID 22746999
94: Rossi P, Di Lorenzo C, Faroni J, Cesarino F, Nappi G. Advice alone vs. structured detoxification programmes for medication overuse headache: a prospective, randomized, open-label trial in transformed migraine patients with low medical needs. Cephalalgia 2006;26(9):1097-105. PMID 16919060
95: Rossi P, Faroni JV, Tassorelli C, Nappi G. Advice alone versus structured detoxification programmes for complicated medication overuse headache (MOH): a prospective, randomized, open-label trial. J Headache Pain 2013;14(1):10. PMID 23565591
96: Sancisi E, Cevoli S, Vignatelli L, et al. Increased prevalence of sleep disorders in chronic headache: a case-control study. Headache 2010;50(9):1464-72. PMID 20572880
97: Sarchielli P, Corbelli I, Messina P, et al. Psychopathological comorbidities in medication-overuse headache: a multicentre clinical study. Eur J Neurol 2015;23(1):85-91. PMID 26228376
98: Scher AI, Stewart WF, Lipton RB. Caffeine as a risk factor for chronic daily headache: a population-based study. Neurology 2004;63(11):2022-7. PMID 15596744
99: Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population--based study. Pain 2003;106:81-9. PMID 14581114
100: Schmidt-Wilcke T, Leinisch E, Straube A, et al. Gray matter decrease in patients with chronic tension type headache. Neurology 2005;65:1483-6. PMID 16275843
101: Schnider P, Aull S, Baumgartner C, et al. Long-term outcome of patients with headache and drug abuse after inpatient withdrawal: five year follow-up. Cephalalgia 1996;16:481-5. PMID 8933992
102: Schramm SH, Moebus S, Lehmann N, et al. The association between stress and headache: a longitudinal population-based study. Cephalalgia 2015;35(10):853-63. PMID 25480807
103: Schwarz A, Farber U, Glaeske G. Daten zu Analgetikakonsum und Analgetikanephropathie in der Bundesrepublik. Öffentliches Gesundheitswesen 1985;47:298. PMID 2931638
104: Schwedt TJ, Alam A, Reed ML, et al. Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study. J Headache Pain 2018;19(1):38. PMID 29797100
105: Schwedt TJ, Buse DC, Argoff CE, et al. Medication overuse and headache burden: results from the CaMEO study. Neurol Clin Pract 2021;11(3):216-26. PMID 34476122
106: Schwedt TJ, Hentz JG, Sahai-Srivastava S, et al. Patient-centered treatment of chronic migraine with medication overuse: a prospective, randomized, pragmatic clinical trial. Neurology 2022;98(14):e1409-21. PMID 35169011
107: Shah AM, Bendtsen L, Zeeberg P, Jensen RH. Reduction of medication costs after detoxification for medication-overuse headache. Headache 2013;53(4):665-72. PMID 23278344
108: Silberstein S, Diamond M, Hindiyeh NA, et al. Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study. J Headache Pain 2020;21(1):120. PMID 33023473
109: Silberstein SD. The impact of fremanezumab on medication overuse in patients with chronic migraine. Presented at the American Headache Society 61st Annual Scientific Meeting, San Francisco, CA, July 11-14, 2019.
110: Silberstein SD, Schulman EA, McFaden Hopkins M. Repetitive intravenous DHE in the treatment of refractory headache. Headache 1990;30:334-9. PMID 2370132
111: Silberstein SD, Silberstein JR. Chronic daily headache: long-term prognosis following inpatient treatment with repetitive intravenous DHE. Headache 1992;32:439-45. PMID 1446987
112: Silverman K, Evans SM, Strain EC, Griffiths RR. Withdrawal syndrome after the double-blind cessation of caffeine consumption. New Engl J Med 1992;327:1109-14. PMID 1528206
113: Srikiatkhachorn A, Anthony M. Platelet serotonin in patients with analgesic-induced headache. Cephalalgia 1996;16(6):423-6. PMID 8902251
114: Srikiatkhachorn A, Tarasub N, Govitrapong P. Effect of chronic analgesic exposure on the central serotonin system: a possible mechanism of analgesic abuse headache. Headache 2000;40(5):343-50. PMID 10849027
115: Straube A, Pfaffenrath V, Ladwig KH, et al. Prevalence of chronic migraine and medication overuse headache in Germany – the German DMKG headache study. Cephalalgia 2010;30(2):207-13. PMID 19489879
116: Suhr B, Evers S, Bauer B, Gralow I, Grotemeyer KH, Husstedt IW. Drug-induced headache: long-term results of stationary versus ambulatory withdrawal therapy. Cephalalgia 1999;19(1):44-9. PMID 10099859
117: Tassorelli C, Jensen R, Allena M, et al. The added value of an electronic monitoring and alerting system in the management of medication-overuse headache: a controlled multicentre study. Cephalalgia 2017;37(12):1115-25. PMID 27440251
118: Tepper SJ, Diener HC, Ashina M, et al. Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial. Neurology 2019;92(20):e2309-20. PMID 30996056
119: Terrazzino S, Sances G, Balsamo F, et al. Role of 2 Common Variants of 5HT2A Gene in Medication Overuse Headache. Headache 2010;50(10):1587-96. PMID 20807249
120: Tfelt-Hansen P, Krabbe AA. Ergotamine abuse: do patients benefit from withdrawal. Cephalalgia 1981;1:29-31. PMID 15645831
121: Tohyama Y, Yamane F, Fikre Merid M, Blier P, Diksic M. Effects of serotonin receptor agonists, TFMPP and CGS12066B, on regional serotonin synthesis in the rat brain: an autoradiographic study. J Neurochemistry 2002;80:788-98. PMID 11948242
122: Tribl GG, Schnider P, Wober C, et al. Are there predictive factors for long-term outcome after withdrawal in drug-induced chronic daily headache. Cephalalgia 2001;21(6):691-6. PMID 11531902
123: van Dusseldorp M, Katan MB. Headache caused by caffeine withdrawal among moderate coffee drinkers switched from ordinary to decaffeinated coffee: a 12 week double blind trial. Br Med J 1990;300:1558-9. PMID 2372623
124: Wang SJ, Fuh JL, Lu SR, Juang KD. Chronic daily headache in adolescents. Prevalence, impact, and medication overuse. Neurology 2006;66(2):193-7. PMID 16434652
125: Westergaard ML, Glumer C, Hansen EH, Jensen RH. Prevalence of chronic headache with and without medication overuse: associations with socioeconomic position and physical and mental health status. Pain 2014;155(10):2005-13. PMID 25020001
126: Westergaard ML, Glümer C, Hansen EH, Jensen RH. Medication overuse, healthy lifestyle behaviour and stress in chronic headache: results from a population-based representative survey. Cephalalgia 2016;36(1):15-28. PMID 25804645
127: Willer L, Jensen RH, Juhler M. Medication overuse as a cause of chronic headache in shunted hydrocephalus patients. J Neurol Neurosurg Psychiatry 2010;81(11):1261-4. PMID 20660917
128: Williams DR, Stark RJ. Intravenous lignocaine (lidocaine) infusion for the treatment of chronic daily headache with substantial medication overuse. Cephalalgia 2003;23:963-71. PMID 14984229
129: Zeeberg P, Olesen J, Jensen R. Probable medication-overuse headache: the effect of a 2-month drug-free period. Neurology 2006;66:1894-8. PMID 16707727
130: Zidverc-Trajkovic J, Pekmezovic T, Jovanovic Z, et al. Medication overuse headache: clinical features predicting treatment outcome at 1-year follow-up. Cephalalgia 2007;27(11):1219-25. PMID 17888081
131: Ziegler DK. Opiate and opioid use in patients with refractory headache. Cephalalgia 1994;14:5-10. PMID 8200026
132: Zobdeh F, Eremenko II, Akan MA, et al. The epigenetics of migraine. Int J Mol Sci 2023;24(11):9127. PMID 37298078

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Chia-Chun Chiang MD

Dr. Chiang of the Mayo Clinic received a consulting fees from eNeura and Satsuma.
See Profile

Editor

Shuu-Jiun Wang MD

Dr. Wang of National Yang-Ming University and Taipei Veterans General Hospital has no relevant financial relationships to disclose.
See Profile

Former Authors

Kenneth L Moore MD
Hans-Christoph Diener MD PhD
Zaza Katsarava MD

Patient Profile

Age range of presentation: 19 to 65+ years
Sex preponderance: female>male, >3:1
Heredity: None
Population groups selectively affected: Patients with primary headache disorders
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-10: Migraine: G43

Other headache syndromes: G44
ICD-11: Migraine: 8A80

Other specified secondary headache: 8A84.Y

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Medication overuse headache

Associated Disorders

Analgesic abuse headache
Analgesic headache
Analgesic rebound headache
Analgesic-induced chronic headache
Analgesic-induced headache
- Chronic daily headache
- Chronic refractory headache
- Drug dependence headache
- Drug-induced headache
- Drug-induced refractory headache
- Ergotamine dependency syndrome
- Ergotamine headache
- Ergotamine-induced headache
- Mixed headache syndrome
- New-onset daily headache
- Rebound headache
- Refractory headache
- Sumatriptan-induced daily headache
- Transformed migraine

Differential Diagnosis

chronic tension-type headache without medication overuse
chronic migraine
transformed migraine
combination headache
hemicrania continua
- idiopathic paroxysmal hemicrania
- cluster headache
- chronic paroxysmal hemicrania
- new daily persistent headache
- viral infection

Also Relevant

Acupuncture in headache treatment
Acute headache: diagnosis
Cluster headache
Dihydroergotamine
Epidemiology of headache
- Headache associated with acute substance use or exposure
- Headache associated with illicit drug use
- Headache guidelines
- Indomethacin-responsive headache syndromes
- Medications and substances causing headache
- Migraine
- Migraine: psychiatric comorbidities
- Sleep and headaches
- Status migrainosus
- Sumatriptan
- Tension-type headache

Clinical Categories

Headache & Pain

Patient Handouts

Headache

Web References

Guidelines

AAN: Headache

Medication overuse headache …

Medication overuse headache

Introduction

Overview

Key points

Historical note and terminology

Table 1. ICHD-3 Section 8.2: Medication Overuse Headache

Clinical manifestations

Presentation and course

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Outcomes

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Primary headache associated with sexual activity

Primary cough headache

Medications and substances causing headache

Headache in children: overview and treatment approaches

Alternating hemiplegia of childhood

Late-life migrainous accompaniments

Complex regional pain syndrome

Headache associated with intracranial neoplasms

Medication overuse headache

Introduction

Overview

Key points

Historical note and terminology

Table 1. ICHD-3 Section 8.2: Medication Overuse Headache

Clinical manifestations

Presentation and course

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Outcomes

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Primary headache associated with sexual activity

Primary cough headache

Medications and substances causing headache

Headache in children: overview and treatment approaches

Alternating hemiplegia of childhood

Late-life migrainous accompaniments

Complex regional pain syndrome

Headache associated with intracranial neoplasms

This is an article preview.
Start a Free Account
to access the full version.